Foghorn therapeutics announces clinical data from phase 1 study of fhd-286, a novel brg1/brm inhibitor, in patients with advanced hematologic malignancies, to be presented at american society of hematology annual meeting

Cambridge, mass., dec. 01, 2023 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that clinical data from the phase 1 dose escalation study of fhd-286 in acute myeloid leukemia (aml) and myelodysplastic syndromes (mds) will be presented at the 65th american society of hematology (ash) annual meeting and exposition, to be held december 9-12, 2023, in san diego, california.
FHTX Ratings Summary
FHTX Quant Ranking